Company profile: Lindis Blood Care
1.1 - Company Overview
Company description
- Provider of a medical device for removing cancer cells from intraoperative blood during cancer surgeries to enable autologous blood transfusion (CATUVAB), and a multicenter clinical certification study (REMOVE) assessing the device’s efficacy and safety in tumor cell removal.
Products and services
- Medical Device Development: Architects a medical-grade system removing cancer cells from intraoperative blood during cancer surgeries, enabling autologous transfusion
- REMOVE Clinical Certification Study: Multicenter evaluation assesses efficacy and safety of CATUVAB® removing tumor cells from intraoperative blood during surgeries
- CATUVAB®: Clinical-grade medical device removes cancer cells from intraoperative blood during surgeries, enabling safe retransfusion of the patient’s blood
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lindis Blood Care
Synta Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule therapeutics to treat cancer and chronic inflammatory diseases, focused on the development and commercialization of these drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synta Pharmaceuticals company profile →
Northwest Biotherapeutics
HQ: United States
Website
- Description: Provider of cancer immunotherapy products, focused on developing and commercializing personalized vaccine candidates: DCVax-L for newly diagnosed glioblastoma multiforme (GBM) in a Phase III trial; DCVax-Direct for direct injection into inoperable solid tumors in a Phase I/II trial; and DCVax-Prostate targeting late-stage, hormone-independent prostate cancer using a proprietary PSMA antigen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Northwest Biotherapeutics company profile →
Med BioGene
HQ: Canada
Website
- Description: Provider of life science-focused genomic-based clinical lab development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Med BioGene company profile →
Stemline
HQ: United States
Website
- Description: Provider of targeted oncology therapies and investigational medicines, including ELZONRIS (tagraxofusp), a CD123-directed therapy approved for BPDCN and being evaluated in AML, CMML, and myelofibrosis, and ORSERDU (elacestrant), an oral SERD approved for ER+, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Pipeline includes SL-801 (XPO1 inhibitor), SL-701 (glioblastoma immunotherapy), and Expanded Access Programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stemline company profile →
Amphista Therapeutics
HQ: United Kingdom
Website
- Description: Provider of next-generation targeted protein degradation therapies and the Eclipsys drug development platform, harnessing the body's natural processes to selectively remove disease-causing proteins. Solutions address a wide range of diseases, including oncology and CNS disorders, and are designed to overcome limitations of first-generation TPD with broad applicability and improved drug properties.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amphista Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lindis Blood Care
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lindis Blood Care
2.2 - Growth funds investing in similar companies to Lindis Blood Care
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lindis Blood Care
4.2 - Public trading comparable groups for Lindis Blood Care
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →